Global Molecular Cytogenetics Market 2017-2021

Global Molecular Cytogenetics Market 2017-2021

About Molecular Cytogenetics

Molecular cytogenetics is the combination of molecular biology and cytogenetics. It increases the resolution and diagnostic utility of cytogenetic analysis. FISH, which is molecular cytogenetic technique, is used for the identification of genetic disorders and the detection of chromosomal genetic abnormalities. CGH, which is also a molecular cytogenetic technique, is used to analyze the variations in copy numbers of the test sample by comparing it with the normal reference sample without using any cell culture.Technavio’s analysts forecast the global molecular cytogenetics market to grow at a CAGR of 10.94% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global molecular cytogenetics market for 2017-2021. To calculate the market size, the report considers the revenue generated from the retail sales of molecular cytogenetics products.The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Technavio's report, Global Molecular Cytogenetics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Thermo Fisher Scientific

Other prominent vendors

• Applied Spectral Imaging
• Biological Industries
• CytoTest
• Cytognomix
• F. Hoffmann-La Roche
• Illumina
• Leica Biosystems
• MetaSystems
• Oxford Gene Technology
• PerkinElmer
• SciGene

Market driver

• Growing aging population and increasing prevalence of chronic diseases
• For a full, detailed list, view our report

Market challenge

• Advent of alternative techniques
• For a full, detailed list, view our report

Market trend

• Increased focus on targeted cancer treatment
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Press Releases

Technavio Announces the Publication of its Research Report – Global Molecular Cytogenetics Market 2017-2021

Technavio recognizes the following companies as the key players in the global molecular cytogenetics market: Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, and Thermo Fisher Scientific.

Other Prominent Vendors in the market are: Applied Spectral Imaging, Biological Industries, CytoTest, Cytognomix, F. Hoffmann-La Roche, Illumina, Leica Biosystems, MetaSystems, Oxford Gene Technology, PerkinElmer, and SciGene.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is increased focus on targeted cancer treatment. Targeted cancer treatment blocks the growth of cancerous cells by interfering with specific cell molecules that are required for carcinogenesis and tumor, instead of interfering with all rapidly dividing cells. The growing prevalence of cancer among men and women is driving the constant development of cancer treatment. Chemotherapy is an important part of cancer treatment.”

According to the report, one driver in the market is growing aging population and increasing prevalence of chronic diseases. The aging population is increasing globally. it has been estimated that the number of people above the age of 65 is expected to increase by more than 200% by 2050 from 2010. With the continuing decline in mortality rates among the aging population, the ratio of aging people and their life expectancy are increasing. This is due to the decline in fertility rates and improvement in life expectancy rates.

Further, the report states that one challenge in the market is advent of alternative techniques. Despite the significant performance advantages and cost benefits of molecular cytogenetics when compared with amplification assays or other molecular in-vitro diagnostic (IVD) tests, FISH's limitation of an error-prone and complex procedural nature, particularly for complex samples such as mucoid respiratory samples or environmental samples, have prevented its routine use for IVD. Some advancements have been made for the removal of traditional DNA probes with peptide probes.

Companies Mentioned

Abbott Laboratories, Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific, Applied Spectral Imaging, Biological Industries, CytoTest, Cytognomix, F. Hoffmann-La Roche, Illumina, Leica Biosystems, MetaSystems, Oxford Gene Technology, PerkinElmer, and SciGene.